Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ACADIA PHARMACEUTICALS INCACAD · Entity 3913 | Director | May 29, 2026 | June 01, 2026 |
| BELLICUM PHARMACEUTICALS, INCBLCM · Entity 107976 | Director | January 03, 2023 | January 05, 2023 |
| CHIMERIX INCCMRX · Entity 80651 | Director | June 20, 2019 | June 24, 2019 |
| CYTOKINETICS INCCYTK · Entity 3528 | Director | July 15, 2026 | July 16, 2026 |
| HALOZYME THERAPEUTICS, INC.HALO · Entity 793 | Director | October 01, 2026 | October 03, 2026 |
| MADRIGAL PHARMACEUTICALS, INC.MDGL · Entity 3441 | Director | June 17, 2026 | June 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ACADIA PHARMACEUTICALS INC
Report date May 29, 2026 · Filed June 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 12,148 |
Reported balance
After 2026-05-29 transaction · row 1
1 source rowRow 1 · 2026-05-29 · Exercise / conversion · Acquired 8,107 · Balance 12,148 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-05-29 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-29 · Exercise / conversion · Disposed 8,107 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F2: The restricted stock units vested in full on May 29, 2026, the date on which an annual meeting of stockholders was held. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 9,311 |
Reported balance
After 2026-05-29 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-05-29 · Grant · Acquired 9,311 · Balance 9,311 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F4: The restricted stock units will vest in full on the earlier of one year following the date of grant or the next annual meeting of stockholders. The reporting person has elected to defer receipt of the shares of common stock underlying the restricted stock units until the earliest of the following: (i) the fifth anniversary of the date of grant of such restricted stock unit award; (ii) the date that is 30 days following the date on which the director ceases to serve as a member of the board of directors of the Issuer or otherwise provide services to the Issuer; and (iii) a change in control of the Issuer as defined in the Issuer's 2024 Equity Incentive Plan, as amended. |
| Director Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.66 · Expires 2036-05-28 | Direct | 16,004 |
Reported balance
After 2026-05-29 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-05-29 · Grant · Acquired 16,004 · Balance 16,004 F3: The shares subject to each stock option will vest quarterly over one year following the date of grant, with the final tranche vesting on the earlier of one year following the date of grant or the next annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.
F2: The restricted stock units vested in full on May 29, 2026, the date on which an annual meeting of stockholders was held.
F3: The shares subject to each stock option will vest quarterly over one year following the date of grant, with the final tranche vesting on the earlier of one year following the date of grant or the next annual meeting of stockholders.
F4: The restricted stock units will vest in full on the earlier of one year following the date of grant or the next annual meeting of stockholders. The reporting person has elected to defer receipt of the shares of common stock underlying the restricted stock units until the earliest of the following: (i) the fifth anniversary of the date of grant of such restricted stock unit award; (ii) the date that is 30 days following the date on which the director ceases to serve as a member of the board of directors of the Issuer or otherwise provide services to the Issuer; and (iii) a change in control of the Issuer as defined in the Issuer's 2024 Equity Incentive Plan, as amended.
BELLICUM PHARMACEUTICALS, INC
Report date January 03, 2023 · Filed January 05, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 109,873 |
Reported balance
After 2023-01-03 transaction · row 1
1 source rowRow 1 · 2023-01-03 · Exercise / conversion · Acquired 60,414 · Balance 109,873 F1: The Reporting Person was granted Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of BLCM common stock. The RSUs vest in full on January 3, 2024, the one-year anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was granted Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of BLCM common stock. The RSUs vest in full on January 3, 2024, the one-year anniversary of the grant date.
CHIMERIX INC
Report date June 20, 2019 · Filed June 24, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.37 · Expires 2029-06-19 | Direct | 21,000 |
Reported balance
After 2019-06-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-06-20 · Grant · Acquired 21,000 · Balance 21,000 F1: The shares subject to the option vest in a series of 12 equal monthly installments from the date of grant; provided, however, that the option shall become fully vested on the date that is the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the Company's 2020 annual stockholder meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option vest in a series of 12 equal monthly installments from the date of grant; provided, however, that the option shall become fully vested on the date that is the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the Company's 2020 annual stockholder meeting.
CYTOKINETICS INC
Report date July 15, 2026 · Filed July 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,390 |
Reported balance
After 2026-07-15 transaction · row 1
1 source rowRow 1 · 2026-07-15 · Grant · Acquired 151 · Balance 3,390 F1: Shares of common stock granted pursuant to the Cytokinetics Equity in lieu of Cash Retainer Program. Shares are fully vested at the time of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares of common stock granted pursuant to the Cytokinetics Equity in lieu of Cash Retainer Program. Shares are fully vested at the time of grant.
HALOZYME THERAPEUTICS, INC.
Report date October 01, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table I · non-derivative | Direct | 1,169 |
Reported balance
After 2026-10-01 transaction · row 1
1 source rowRow 1 · 2026-10-01 · Grant · Acquired 1,169 · Balance 1,169 F1: Represents restricted stock units granted under the Issuer's director compensation program. Each stock unit represents the right to receive one share of common stock and is scheduled to vest on the date of the Issuer's 2027 annual meeting of stockholders. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $106.94 · Expires 2036-10-01 | Direct | 1,775 |
Reported balance
After 2026-10-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-10-01 · Grant · Acquired 1,775 · Balance 1,775 F2: Represents stock options granted under the Issuer's director compensation program. This grant will vest in full on the date of the Issuer's 2027 annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units granted under the Issuer's director compensation program. Each stock unit represents the right to receive one share of common stock and is scheduled to vest on the date of the Issuer's 2027 annual meeting of stockholders.
F2: Represents stock options granted under the Issuer's director compensation program. This grant will vest in full on the date of the Issuer's 2027 annual meeting of stockholders.
MADRIGAL PHARMACEUTICALS, INC.
Report date June 17, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,081 |
Reported balance
After 2026-06-17 transaction · row 1
1 source rowRow 1 · 2026-06-17 · Grant · Acquired 454 · Balance 3,081 F1: Represents a grant of restricted stock units which vest on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, provided the Reporting Person continues in service with the Issuer on such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $499.86 · Expires 2036-06-17 | Direct | 766 |
Reported balance
After 2026-06-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-17 · Grant · Acquired 766 · Balance 766 F2: The option vests as to 100% of underlying shares on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, provided the Reporting Person continues in service with the Issuer on such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a grant of restricted stock units which vest on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, provided the Reporting Person continues in service with the Issuer on such date.
F2: The option vests as to 100% of underlying shares on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, provided the Reporting Person continues in service with the Issuer on such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2026 Filed Oct 3, 2026 00:43 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantOption to Purchase Common Stock · Derivative | 1,775 | $0.00 Strike: $106.94 | $0.00 |
DisclosureSEC source: 0001159036-26-000136 · wk-form4_1790973818.xml · derivative · entry 2 Daly James M · CIK 0001560782 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,775 Underlying: Common Stock · 1,775 shares Expires 2036-10-01 F2 · derivative.exercise_date: Represents stock options granted under the Issuer's director compensation program. This grant will vest in full on the date of the Issuer's 2027 annual meeting of stockholders. Read SEC document |
| October 01, 2026 Filed Oct 3, 2026 00:43 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantRestricted Stock Units | 1,169 | $0.00 | $0.00 |
DisclosureSEC source: 0001159036-26-000136 · wk-form4_1790973818.xml · nonDerivative · entry 1 Daly James M · CIK 0001560782 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,169 F1 · shares: Represents restricted stock units granted under the Issuer's director compensation program. Each stock unit represents the right to receive one share of common stock and is scheduled to vest on the date of the Issuer's 2027 annual meeting of stockholders. Read SEC document |
| July 15, 2026 Filed Jul 16, 2026 20:28 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 151 | $82.62 | $12,475.62 |
DisclosureSEC source: 0001061983-26-000078 · form4.xml · nonDerivative · entry 1 Daly James M · CIK 0001560782 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,390 F1 · kind: Shares of common stock granted pursuant to the Cytokinetics Equity in lieu of Cash Retainer Program. Shares are fully vested at the time of grant. Read SEC document |
| June 17, 2026 Filed Jun 18, 2026 20:16 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantStock Option (Right to Buy) · Derivative | 766 | $0.00 Strike: $499.86 | $0.00 |
DisclosureSEC source: 0001628280-26-044307 · wk-form4_1781813798.xml · derivative · entry 2 Daly James M · CIK 0001560782 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 766 Underlying: Common Stock · 766 shares Expires 2036-06-17 F2 · derivative.exercise_date: The option vests as to 100% of underlying shares on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, provided the Reporting Person continues in service with the Issuer on such date. Read SEC document |
| June 17, 2026 Filed Jun 18, 2026 20:16 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantCommon Stock | 454 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-044307 · wk-form4_1781813798.xml · nonDerivative · entry 1 Daly James M · CIK 0001560782 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,081 F1 · kind: Represents a grant of restricted stock units which vest on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, provided the Reporting Person continues in service with the Issuer on such date. Read SEC document |
| May 29, 2026 Filed Jun 1, 2026 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantRestricted Stock Units · Derivative | 9,311 | $0.00 | $0.00 |
DisclosureSEC source: 0001560782-26-000002 · form4-06012026_060601.xml · derivative · entry 4 Daly James M · CIK 0001560782 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,311 Underlying: Common Stock · 9,311 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F4 · derivative.exercise_date: The restricted stock units will vest in full on the earlier of one year following the date of grant or the next annual meeting of stockholders. The reporting person has elected to defer receipt of the shares of common stock underlying the restricted stock units until the earliest of the following: (i) the fifth anniversary of the date of grant of such restricted stock unit award; (ii) the date that is 30 days following the date on which the director ceases to serve as a member of the board of directors of the Issuer or otherwise provide services to the Issuer; and (iii) a change in control of the Issuer as defined in the Issuer's 2024 Equity Incentive Plan, as amended. F4 · derivative.expiration_date: The restricted stock units will vest in full on the earlier of one year following the date of grant or the next annual meeting of stockholders. The reporting person has elected to defer receipt of the shares of common stock underlying the restricted stock units until the earliest of the following: (i) the fifth anniversary of the date of grant of such restricted stock unit award; (ii) the date that is 30 days following the date on which the director ceases to serve as a member of the board of directors of the Issuer or otherwise provide services to the Issuer; and (iii) a change in control of the Issuer as defined in the Issuer's 2024 Equity Incentive Plan, as amended. Read SEC document |
| May 29, 2026 Filed Jun 1, 2026 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantDirector Stock Options (Right to Buy) · Derivative | 16,004 | $0.00 Strike: $21.66 | $0.00 |
DisclosureSEC source: 0001560782-26-000002 · form4-06012026_060601.xml · derivative · entry 3 Daly James M · CIK 0001560782 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,004 Underlying: Common Stock · 16,004 shares Expires 2036-05-28 F3 · derivative.exercise_date: The shares subject to each stock option will vest quarterly over one year following the date of grant, with the final tranche vesting on the earlier of one year following the date of grant or the next annual meeting of stockholders. Read SEC document |
| May 29, 2026 Filed Jun 1, 2026 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 8,107 | $0.00 | $0.00 |
DisclosureSEC source: 0001560782-26-000002 · form4-06012026_060601.xml · derivative · entry 2 Daly James M · CIK 0001560782 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,107 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F2 · derivative.exercise_date: The restricted stock units vested in full on May 29, 2026, the date on which an annual meeting of stockholders was held. F2 · derivative.expiration_date: The restricted stock units vested in full on May 29, 2026, the date on which an annual meeting of stockholders was held. Read SEC document |
| May 29, 2026 Filed Jun 1, 2026 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 8,107 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001560782-26-000002 · form4-06012026_060601.xml · nonDerivative · entry 1 Daly James M · CIK 0001560782 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,148 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. Read SEC document |
| May 27, 2026 Filed May 27, 2026 23:14 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 4,301 | $0.00 Strike: $77.15 | $0.00 |
DisclosureSEC source: 0001061983-26-000061 · form4.xml · derivative · entry 2 Daly James M · CIK 0001560782 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,301 Underlying: Common Stock · 4,301 shares Expires 2036-05-26 Read SEC document |
| May 27, 2026 Filed May 27, 2026 23:14 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 2,851 | $0.00 | $0.00 |
DisclosureSEC source: 0001061983-26-000061 · form4.xml · nonDerivative · entry 1 Daly James M · CIK 0001560782 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,239 Read SEC document |
| April 15, 2026 Filed Apr 15, 2026 22:32 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 191 | $65.37 | $12,485.67 |
DisclosureSEC source: 0001061983-26-000037 · form4.xml · nonDerivative · entry 1 Daly James M · CIK 0001560782 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 388 F1 · kind: Shares of common stock granted pursuant to Director Equity in Lieu of Cash Retainer Program. Shares are fully vested. Read SEC document |
| January 15, 2026 Filed Jan 20, 2026 21:17 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 197 | $63.44 | $12,497.68 |
DisclosureSEC source: 0001061983-26-000010 · form4.xml · nonDerivative · entry 1 Daly James M · CIK 0001560782 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 197 F1 · kind: Fully vested shares of common stock received in lieu of cash retainer pursuant to Equity in Lieu of Cash Retainer Option available to members of Issuer's Board of Directors. Read SEC document |
| November 10, 2025 Filed Nov 12, 2025 23:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 30,000 | $22.37 | $670,983.00 |
DisclosureSEC source: 0001560782-25-000006 · form4-11122025_061101.xml · nonDerivative · entry 1 Daly James M · CIK 0001560782 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,041 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.14 to $22.63, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| August 19, 2025 Filed Aug 20, 2025 12:04 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 27,450 | $0.00 Strike: $37.84 | $0.00 |
DisclosureSEC source: 0001127602-25-020750 · form4.xml · derivative · entry 1 Daly James M · CIK 0001560782 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,450 Underlying: Common Stock · 27,450 shares Expires 2035-08-19 F1 · kind: Initial Grant to New Director. Read SEC document |
| June 20, 2025 Filed Jun 24, 2025 20:34 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantStock Option (Right to Buy) · Derivative | 1,290 | $0.00 Strike: $285.73 | $0.00 |
DisclosureSEC source: 0001628280-25-032850 · wk-form4_1750797254.xml · derivative · entry 2 Daly James M · CIK 0001560782 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,290 Underlying: Common Stock · 1,290 shares Expires 2035-06-20 F2 · derivative.exercise_date: The option vests as to 100% of underlying shares on the date of the Issuer's annual meeting of stockholders to be held in 2026, provided that the Reporting Person continues to serve as a director of the Issuer until such date. Read SEC document |
| June 20, 2025 Filed Jun 24, 2025 20:34 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantCommon Stock | 715 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-032850 · wk-form4_1750797254.xml · nonDerivative · entry 1 Daly James M · CIK 0001560782 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,627 F1 · kind: Represents a grant of restricted stock units, which vest on the date of the Issuer's annual meeting of stockholders to be held in 2026, provided the Reporting Person continues in service with the Issuer on such date. Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 22:05 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantRestricted Stock Units · Derivative | 8,107 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-015271 · form4-06022025_060603.xml · derivative · entry 4 Daly James M · CIK 0001560782 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,107 Underlying: Common Stock · 8,107 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F4 · derivative.exercise_date: The restricted stock units will vest in full on the earlier of one year following the date of grant or the next annual meeting of stockholders. F4 · derivative.expiration_date: The restricted stock units will vest in full on the earlier of one year following the date of grant or the next annual meeting of stockholders. Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 22:05 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantDirector Stock Options (Right to Buy) · Derivative | 13,793 | $0.00 Strike: $22.29 | $0.00 |
DisclosureSEC source: 0001415889-25-015271 · form4-06022025_060603.xml · derivative · entry 3 Daly James M · CIK 0001560782 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,793 Underlying: Common Stock · 13,793 shares Expires 2035-05-28 F3 · derivative.exercise_date: The shares subject to each stock option will vest quarterly over one year following the date of grant, with the final tranche vesting on the earlier of one year following the date of grant or the next annual meeting of stockholders. Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 22:05 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 9,387 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-015271 · form4-06022025_060603.xml · derivative · entry 2 Daly James M · CIK 0001560782 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,387 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F2 · derivative.exercise_date: The restricted stock units vested in full on May 29, 2025, the date on which an annual meeting of stockholders was held. F2 · derivative.expiration_date: The restricted stock units vested in full on May 29, 2025, the date on which an annual meeting of stockholders was held. Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 22:05 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 9,387 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-015271 · form4-06022025_060603.xml · nonDerivative · entry 1 Daly James M · CIK 0001560782 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,041 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. Read SEC document |
| February 27, 2025 Filed Feb 28, 2025 21:31 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $111.06 | $0.00 |
DisclosureSEC source: 0001628280-25-009079 · wk-form4_1740778263.xml · derivative · entry 7 Daly James M · CIK 0001560782 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,000 shares Expires 2025-06-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares underlying this option are fully vested and exercisable. Read SEC document |
| February 27, 2025 Filed Feb 28, 2025 21:31 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionStock Option (Right to Buy) · Derivative | 9,470 | $0.00 Strike: $65.06 | $0.00 |
DisclosureSEC source: 0001628280-25-009079 · wk-form4_1740778263.xml · derivative · entry 6 Daly James M · CIK 0001560782 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,470 shares Expires 2025-06-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares underlying this option are fully vested and exercisable. Read SEC document |
| February 27, 2025 Filed Feb 28, 2025 21:31 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 770 | $348.94 | $268,686.34 |
DisclosureSEC source: 0001628280-25-009079 · wk-form4_1740778263.xml · nonDerivative · entry 5 Daly James M · CIK 0001560782 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,912 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $348.73 to $349.705, inclusive. Read SEC document |
| February 27, 2025 Filed Feb 28, 2025 21:31 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 14,302 | $347.39 | $4,968,371.78 |
DisclosureSEC source: 0001628280-25-009079 · wk-form4_1740778263.xml · nonDerivative · entry 4 Daly James M · CIK 0001560782 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,682 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $347.36 to $348.225, inclusive. Read SEC document |
| February 27, 2025 Filed Feb 28, 2025 21:31 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 398 | $346.90 | $138,067.43 |
DisclosureSEC source: 0001628280-25-009079 · wk-form4_1740778263.xml · nonDerivative · entry 3 Daly James M · CIK 0001560782 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,984 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $346.34 to $347.18, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below. Read SEC document |
| February 27, 2025 Filed Feb 28, 2025 21:31 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionCommon Stock | 6,000 | $111.06 | $666,360.00 |
DisclosureSEC source: 0001628280-25-009079 · wk-form4_1740778263.xml · nonDerivative · entry 2 Daly James M · CIK 0001560782 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,382 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 27, 2025 Filed Feb 28, 2025 21:31 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionCommon Stock | 9,470 | $65.06 | $616,118.20 |
DisclosureSEC source: 0001628280-25-009079 · wk-form4_1740778263.xml · nonDerivative · entry 1 Daly James M · CIK 0001560782 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,382 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 25, 2024 Filed Jun 28, 2024 01:42 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantStock Option (Right to Buy) · Derivative | 1,105 | $0.00 Strike: $280.04 | $0.00 |
DisclosureSEC source: 0000950170-24-078750 · ownership.xml · derivative · entry 2 Daly James M · CIK 0001560782 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,105 Underlying: Common Stock · 1,105 shares Expires 2031-06-25 F2 · derivative.exercise_date: The option vests as to 100% of underlying shares on the first anniversary of the grant date, provided that the Reporting Person continues to serve as a director of the Issuer until such anniversary date. Read SEC document |
| June 25, 2024 Filed Jun 28, 2024 01:42 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantCommon Stock | 714 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-078750 · ownership.xml · nonDerivative · entry 1 Daly James M · CIK 0001560782 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,912 F1 · shares: Represents a grant of restricted stock units, which vest on June 25, 2025, provided the Reporting Person continues in service with the Issuer on such date. Read SEC document |
| May 29, 2024 Filed May 31, 2024 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantRestricted Stock Units · Derivative | 9,387 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-015087 · form4-05312024_060512.xml · derivative · entry 4 Daly James M · CIK 0001560782 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,387 Underlying: Common Stock · 9,387 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F4 · derivative.exercise_date: The restricted stock units will vest in full on the earlier of one year following the date of grant or the next annual meeting of stockholders. F4 · derivative.expiration_date: The restricted stock units will vest in full on the earlier of one year following the date of grant or the next annual meeting of stockholders. Read SEC document |
| May 29, 2024 Filed May 31, 2024 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantDirector Stock Options (Right to Buy) · Derivative | 15,959 | $0.00 Strike: $14.62 | $0.00 |
DisclosureSEC source: 0001415889-24-015087 · form4-05312024_060512.xml · derivative · entry 3 Daly James M · CIK 0001560782 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,959 Underlying: Common Stock · 15,959 shares Expires 2034-05-28 F3 · derivative.exercise_date: The shares subject to each stock option will vest quarterly over one year following the date of grant, with the final tranche vesting on the earlier of one year following the date of grant or the next annual meeting of stockholders. Read SEC document |
| May 29, 2024 Filed May 31, 2024 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 6,652 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-015087 · form4-05312024_060512.xml · derivative · entry 2 Daly James M · CIK 0001560782 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,652 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F2 · derivative.exercise_date: The restricted stock units vested in full on May 29, 2024, the date on which an annual meeting of stockholders was held. F2 · derivative.expiration_date: The restricted stock units vested in full on May 29, 2024, the date on which an annual meeting of stockholders was held. Read SEC document |
| May 29, 2024 Filed May 31, 2024 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 6,652 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-015087 · form4-05312024_060512.xml · nonDerivative · entry 1 Daly James M · CIK 0001560782 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,654 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. Read SEC document |
| April 02, 2024 Filed Apr 4, 2024 00:41 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,912 | $0.00 Strike: $105.08 | $0.00 |
DisclosureSEC source: 0000899243-24-000243 · doc4.xml · derivative · entry 22 Daly James M · CIK 0001560782 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,912 shares Expires 2024-06-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F18 · derivative.exercise_date: The shares underlying this option are fully vested and exercisable. Read SEC document |
| April 02, 2024 Filed Apr 4, 2024 00:41 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 200 | $248.45 | $49,690.16 |
DisclosureSEC source: 0000899243-24-000243 · doc4.xml · nonDerivative · entry 19 Daly James M · CIK 0001560782 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,198 F1 · kind: (1) These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023. F17 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $247.96 to $248.72, inclusive. Read SEC document |
| April 02, 2024 Filed Apr 4, 2024 00:41 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 43 | $247.03 | $10,622.47 |
DisclosureSEC source: 0000899243-24-000243 · doc4.xml · nonDerivative · entry 18 Daly James M · CIK 0001560782 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,398 F1 · kind: (1) These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023. F16 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $246.72 to $247.24, inclusive. Read SEC document |
| April 02, 2024 Filed Apr 4, 2024 00:41 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 557 | $246.30 | $137,186.76 |
DisclosureSEC source: 0000899243-24-000243 · doc4.xml · nonDerivative · entry 17 Daly James M · CIK 0001560782 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,441 F1 · kind: (1) These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023. F16 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $246.72 to $247.24, inclusive. Read SEC document |
| April 02, 2024 Filed Apr 4, 2024 00:41 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 2,991 | $244.89 | $732,479.75 |
DisclosureSEC source: 0000899243-24-000243 · doc4.xml · nonDerivative · entry 16 Daly James M · CIK 0001560782 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,998 F1 · kind: (1) These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023. F15 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $245.62 to $246.54, inclusive. Read SEC document |
| April 02, 2024 Filed Apr 4, 2024 00:41 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 6,279 | $244.19 | $1,533,285.96 |
DisclosureSEC source: 0000899243-24-000243 · doc4.xml · nonDerivative · entry 15 Daly James M · CIK 0001560782 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,989 F1 · kind: (1) These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023. F14 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $244.61 to $245.53, inclusive. Read SEC document |
| April 02, 2024 Filed Apr 4, 2024 00:41 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 842 | $243.26 | $204,821.47 |
DisclosureSEC source: 0000899243-24-000243 · doc4.xml · nonDerivative · entry 14 Daly James M · CIK 0001560782 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,268 F1 · kind: (1) These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023. F13 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $243.60 to $244.58, inclusive. Read SEC document |
| April 02, 2024 Filed Apr 4, 2024 00:41 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionCommon Stock | 10,912 | $105.08 | $1,146,632.96 |
DisclosureSEC source: 0000899243-24-000243 · doc4.xml · nonDerivative · entry 13 Daly James M · CIK 0001560782 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,110 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $242.58 to $243.56, inclusive. Read SEC document |
| April 01, 2024 Filed Apr 4, 2024 00:41 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,577 | $0.00 Strike: $105.08 | $0.00 |
DisclosureSEC source: 0000899243-24-000243 · doc4.xml · derivative · entry 21 Daly James M · CIK 0001560782 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,912 Underlying: Common Stock · 1,577 shares Expires 2024-06-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F18 · derivative.exercise_date: The shares underlying this option are fully vested and exercisable. Read SEC document |
| April 01, 2024 Filed Apr 4, 2024 00:41 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $100.45 | $0.00 |
DisclosureSEC source: 0000899243-24-000243 · doc4.xml · derivative · entry 20 Daly James M · CIK 0001560782 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2024-06-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F18 · derivative.exercise_date: The shares underlying this option are fully vested and exercisable. Read SEC document |
| April 01, 2024 Filed Apr 4, 2024 00:41 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 274 | $266.91 | $73,132.02 |
DisclosureSEC source: 0000899243-24-000243 · doc4.xml · nonDerivative · entry 12 Daly James M · CIK 0001560782 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,198 F1 · kind: (1) These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023. F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $266.73 to $267.21, inclusive. Read SEC document |
| April 01, 2024 Filed Apr 4, 2024 00:41 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 500 | $265.49 | $132,743.00 |
DisclosureSEC source: 0000899243-24-000243 · doc4.xml · nonDerivative · entry 11 Daly James M · CIK 0001560782 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,472 F1 · kind: (1) These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $265.35 to $265.64, inclusive. Read SEC document |
| April 01, 2024 Filed Apr 4, 2024 00:41 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 351 | $264.89 | $92,976.67 |
DisclosureSEC source: 0000899243-24-000243 · doc4.xml · nonDerivative · entry 10 Daly James M · CIK 0001560782 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,972 F1 · kind: (1) These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $264.11 to $265.07, inclusive. Read SEC document |
| April 01, 2024 Filed Apr 4, 2024 00:41 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 178 | $263.31 | $46,869.77 |
DisclosureSEC source: 0000899243-24-000243 · doc4.xml · nonDerivative · entry 9 Daly James M · CIK 0001560782 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,323 F1 · kind: (1) These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $263.09 to $264.07, inclusive. Read SEC document |
| April 01, 2024 Filed Apr 4, 2024 00:41 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 800 | $262.01 | $209,604.00 |
DisclosureSEC source: 0000899243-24-000243 · doc4.xml · nonDerivative · entry 8 Daly James M · CIK 0001560782 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,501 F1 · kind: (1) These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $261.59 to $262.15, inclusive. Read SEC document |
| April 01, 2024 Filed Apr 4, 2024 00:41 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 200 | $259.11 | $51,822.00 |
DisclosureSEC source: 0000899243-24-000243 · doc4.xml · nonDerivative · entry 7 Daly James M · CIK 0001560782 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,301 F1 · kind: (1) These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $259.10 to $259.12, inclusive. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.